GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inari Medical Inc (NAS:NARI) » Definitions » Depreciation, Depletion and Amortization

Inari Medical (Inari Medical) Depreciation, Depletion and Amortization : $12.4 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inari Medical Depreciation, Depletion and Amortization?

Inari Medical's depreciation, depletion and amortization for the three months ended in Mar. 2024 was $4.6 Mil. Its depreciation, depletion and amortization for the trailing twelve months (TTM) ended in Mar. 2024 was $12.4 Mil.


Inari Medical Depreciation, Depletion and Amortization Historical Data

The historical data trend for Inari Medical's Depreciation, Depletion and Amortization can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inari Medical Depreciation, Depletion and Amortization Chart

Inari Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Depreciation, Depletion and Amortization
Get a 7-Day Free Trial 0.61 1.39 4.31 7.12 10.74

Inari Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Depreciation, Depletion and Amortization Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.97 2.14 2.17 3.45 4.62

Inari Medical Depreciation, Depletion and Amortization Calculation

Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.

Depletion and amortization are synonyms for depreciation.

Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inari Medical  (NAS:NARI) Depreciation, Depletion and Amortization Explanation

One of the key tenets of Generally Accepted Accounting Principles (GAAP) is the matching principle. The matching principle states that companies should report associated costs and benefits at the same time.

For example:

If a company buys a $300 million cruise ship in 1982 and then sells tickets to passengers for the next 30 years, the company should not report a $300 million expense in 1982 and then ticket sales for 1982 through 2012. Instead, the company should spread the purchase price of the ship (the cost) over the same time period it sells tickets (the benefit).

To create income statements that meet the matching principle, accountants use an expense called depreciation.

So, instead of reporting a $300 million purchase expense in 1982, the company might:

Report a $30 million depreciation expense in 1982, 1983, 1984...and every year after that for the 30 years the company expects to sell tickets to passengers on this cruise ship.

To calculate depreciation, a company must make estimates and choices such as:

The cost of the asset
The useful life of the asset
The salvage value of the asset at the end of its useful life
And a way of spreading the cost of the asset to match the time when the asset provides benefits

The range of different ways of spreading the cost under GAAP accounting is too long to list. However, public companies in the United States explain their depreciation choices to shareholders in a note to their financial statements. It is critical that investors read this note. Investors can find this note in the company's 10-K.

Past depreciation expenses accumulate on the balance sheet. Most public companies choose not to show this contra asset account on the balance sheet they present to shareholders. Instead, they simply show a single item. This single asset item may be marked Net. Such as Property, Plant, and Equipment - Net. It is actually the asset account netted against the contra asset account.

A contra asset account is an account that offsets an asset account. So, for example a company might have:

Property, Plant, and Equipment - Gross: $150 million
Accumulated Depreciation: $120 million
Property, Plant, and Equipment - Net: $30 million

In this case, the only item likely to be shown on the balance sheet is Property, Plant, and Equipment - Net. This is the cost of the company's property, plant, and equipment (asset account) minus the accumulated depreciation (the contra asset account). It means the company's assets cost $150 million, the company has reported $120 million in depreciation expense over the years, and the company is now reporting the assets have a book value of $30 million.

It is possible for a company to have fully depreciated assets on its balance sheet. This means the company's estimate of the useful life of the asset was shorter than the asset's actual useful life. As a result, the asset - although it is still being used - is carried on the balance sheet at its salvage value.

This is a reminder that depreciation involves estimates and choices. It is not an infallible process.

Companies do not have cash layout for depreciation. Therefore, depreciation is added back in the cash flow statement.

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when it purchases them. Both Warren Buffett and Charlie Munger hate the idea of EDITDA because depreciation is not included as an expense. Warren Buffett even jokingly said We prefer earnings before everything when criticizing the abuse of EDITDA.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Inari Medical Depreciation, Depletion and Amortization Related Terms

Thank you for viewing the detailed overview of Inari Medical's Depreciation, Depletion and Amortization provided by GuruFocus.com. Please click on the following links to see related term pages.


Inari Medical (Inari Medical) Business Description

Industry
Traded in Other Exchanges
Address
6001 Oak Canyon, Suite 100, Irvine, CA, USA, 92618
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism. The company generates revenue from the sale of ClotTriever and FlowTriever systems directly to hospitals located in the United States. Majority of revenue is generated from FlowTriever system.
Executives
William Hoffman director, officer: President and CEO C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Mitch C. Hill, officer: Chief Financial Officer 1009 TENNYSON DRIVE, SOUTHLAKE TX 76902
Andrew Hykes officer: Chief Operating Officer C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Thomas Tu officer: Chief Medical Officer C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Donald B Milder director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert Keith Warner director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Catherine M. Szyman director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Cynthia L Lucchese director 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Rebecca Chambers director 3052 ORCHARD DR., SAN JOSE CA 95134
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
Cooperatieve Gilde Healthcare Iv U.a. 10 percent owner NEWTONLANN 51, UTRECHT P7 3508AB
Kirk G. Nielsen director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Gilde Healthcare Iv Management B.v. 10 percent owner NEWTONLAAN 91, UTRECHT P7 3584 BP
Gilde Healthcare Holding B.v. 10 percent owner NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB